<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 26, 2000
VIROPHARMA INCORPORATED
-----------------------
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
</TABLE>
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5 - OTHER EVENTS.
ViroPharma Incorporated (the "Company") announced in a press release dated
April 11, 2000 (the "Press Release") the preliminary results of three Phase 3
clinical studies of pleconaril in two disease indications: viral respiratory
infection and viral meningitis. The Press Release was also filed as an exhibit
to a Current Report on Form 8-K on the same date.
The Company is pursuing additional trials for viral respiratory infection
as stated in the Press Release. In addition, the Company may conduct an
exploratory study in adult patients suffering from viral meningitis in order to
better understand the disease and to determine the potential treatment benefit
of pleconaril for these patients. The Company anticipates that the
exploratory study could take up to two years to complete.
This report contains forward-looking statements, including statements
relating to the Company's anticipated schedule for conducting clinical trials.
Pleconaril currently is in clinical trials. There can be no assurance that
planned or ongoing clinical trials can be successfully concluded or concluded in
accordance with the Company's anticipated schedule. The conduct of clinical
trials and acquiring regulatory approval for investigational pharmaceutical
products are subject to risks and uncertainties. Neither the FDA nor any other
regulatory authority has approved pleconaril or any of ViroPharma's other
product candidates for commercialization. There can be no assurance that FDA or
other regulatory authority approval for pleconaril or any other product
candidate under development by ViroPharma will be granted on a timely basis or
at all. Even if approved, there can be no assurance that pleconaril will
achieve market acceptance. These factors, and other factors that could cause
future results to differ materially from the expectations expressed in this
report, include, but are not limited to, those described in ViroPharma's
1999 Annual Report on Form 10-K filed with the Securities and Exchange
Commission. The forward-looking statements contained in this report may
become outdated over time. ViroPharma does not assume any responsibility for
updating any forward-looking statements.
ITEM 7 - FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
None.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: May 26, 2000 By: /s/ Claude H. Nash
------------------
Claude H. Nash
President and Chief Executive Officer
